IRVINE, Calif., Nov. 4, 2012 /PRNewswire/ -- Dr. Douglas Harrington, CEO of Aviir, Inc., joined a host of influential companies and experts at the Los Angeles Ultimate Women's Expo on Saturday, October 27 to discuss America's leading threat to women: Heart Disease. Dr. Harrington's lecture "Everything You Ever Wanted to Know About Heart Disease But Were Afraid to Ask" provided a higher level of insight into the disease and how women can empower themselves, improving their cardiovascular health. The speaking session began at 12:30 PM, at the Los Angeles Convention Center and was sponsored by GuardaHeart Foundation.
(Photo: http://photos.prnewswire.com/prnh/20121104/LA05795 )
As CEO of Aviir, Inc., Dr. Harrington brings more than 25 years of experience in the commercialization of health care technology. Aviir, Inc. is an Irvine-based biotechnology company that develops innovative diagnostic and laboratory tests. Dr. Harrington's personal mission is to offer clarity to heart disease through reliable assessments and prevention.
The Los Angeles Ultimate Women's Expo sought out some of the best seminar speakers around the world to participate in their event, which is held in several cities across the country.
GuardaHeart sponsors heart risk assessments through an on-going collaboration with Aviir. Far too many lives continue to be needlessly lost to heart disease, while many more are burdened with the medical debt caused by surviving a heart attack.
"Heart Disease remains the leading cause of death in the US, claiming almost 600,000 lives each year, yet many are unaware that 80% of heart disease is preventable through lifestyle modification," said Dr. Harrington. Through GuardaHeart's movement "Pledge to SaveThe1" individuals are empowered and equipped to make these critical lifestyle modifications.
Dr. Harrington also discussed an innovative blood test, developed through an Aviir/Stanford University cardiology collaboration, which identifies an individuals' cardiac risk in a five-year timeframe. "This timeframe allows preventive measures to be implemented," continued Dr. Harrington. "Our mission is to improve healthcare and encourage timely preventive strategies by providing this unique medical information."
About Aviir, Inc.
Aviir was founded in 2005 by cardiologists and scientists from the Stanford University School of Medicine to focus on discovery, development and commercialization of innovative diagnostic tests. The biotechnology company specializes in developing proprietary diagnostic tests that will assist in identifying patients that are truly at high risk for the development of a cardiac event. Aviir's proprietary MIRisk and TruRisk assessments objectively identify, by a simple blood draw, individuals who are at a high risk of a cardiac event over the next five years. Aviir's CLIA laboratory (Irvine, CA) complements these novel tests with a wide range of additional tests for risk assessment and therapeutic monitoring of cardiovascular disease and related metabolic disorders including pharmacogenomic and genetic tests. The company has adopted a unique clinical laboratory service model to provide physicians better diagnostic tools that improve cardiovascular health of their patients. The company is privately owned and funded by leading life science venture capital firms. Please visit www.aviir.com for more information.
About Los Angeles Ultimate Women's Expo
The Ultimate Women's Expo unites thousands of women with the most respected companies and brands that provide valuable products and services designed to enrich the lives of women. Indulge with the very best Los Angeles has to offer in shopping, fashion, food, entertainment, cosmetics, health and wellness and travel. Expo hours are October 27 and 28 from 10:00 AM. For more information, visit: http://www.lawomensexpo.com.
For media inquiries, please contact: Dina Scaglione (949) 398-6320 email@example.com
For Interviews at the Expo please contact:
YM & Associates
PR | Marketing | Branding | Business Development
California | New York
949.244.9769 | 310.499.0906 Fax
SOURCE Aviir, Inc.